pablo

Columbus understands the mRNA production supply chain and backed Viralgen's €4B exit; their operational knowledge in manufacturing infrastructure makes them a key partner for hard-tech health investing.

Hims & Hers operates a three-layer flywheel — teleconsultation, owned pharmacy fulfillment, and performance marketing — enabling end-to-end control of high-volume conditions like obesity and hair loss, with a path to several billion dollars in valuation.

Admit's blood-based assay detects beta-amyloid presence and predicts Alzheimer's progression to dementia, but commercial viability hinges on actionability — currently limited by lack of disease-modifying treatments and personalized intervention evidence.

After 9 years and several million in revenue, BB Scripts cannot scale beyond a ceiling, illustrating why point solutions in digital health generate insufficient IRR for venture portfolios despite decent business fundamentals.

Virta's employer-paid program reverses type 2 diabetes without insulin, reducing costly complications; now positioned as a mandatory step before GLP-1 coverage, creating a massive B2B2C moat with unicorn valuation and likely IPO within the year.

Butterfly's phone-connected ultrasound democratizes imaging access for remote areas, and the fund realized a very good return at IPO; however, the remaining challenge is AI-assisted interpretation to replace years of sonographer training.

Happy Robot is positioned as an enterprise agent platform that begins with concrete logistics workflows and then compounds context across functions. Its traction with top freight brokers, trucking companies, ocean carriers, and DHL suggests the wedge can expand beyond simple voice support into higher-value operational decisions.